



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/777,008
Applicant : MARTIN, Emil, *et al.*
Filed : February 11, 2004
For : Treatment or Prevention of cGMP-dependent Pathophysiology
with a Mutant Variant of Soluble Guanylyl Cyclase
TC/A.U. : 1651
Examiner : GITOMER, Ralph J.

Confirmation No. 3412

Customer No.: 23505
Atty. Dkt. No.: 2105-00101
Date: May 2, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:


This Information Disclosure Statement, including completed Form PTO-1449, comprises a list of pertinent art of which Applicants are aware.


The submission of this Information Disclosure Statement and the references submitted therewith is not an admission that the art cited is "prior" with respect to the present invention, nor is it a representation, that no better art exists. Applicants hereby reserve the right to swear behind or otherwise disprove any alleged "prior" nature of any art cited should the facts support and the situation warrant such an action. It is submitted that the art cited does not constitute a bar to the patentability of Applicants' invention under 35 U.S.C. § 102 or § 103.

No Office Action on the merits has been received in the present application. In the event that an Office Action dated prior to the mailing date of this Information Disclosure Statement has been issued, please charge Deposit Account 03-2769, Conley Rose, P.C., in the amount of \$180, so that this Information Disclosure Statement may be considered under Rule 1.97(c).

05/04/2005 FHETEK11 00000036 032769 10777008
01 FC:1806 180.00 DA

Respectfully submitted,


Carol G. Mintz
Reg. No. 38,561
CONLEY, ROSE, P.C.
P. O. Box 3267
Houston, Texas 77253-3267
(713) 238-8000
AGENT FOR APPLICANTS



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/777.008
				Filing Date	February 11, 2004
				First Named Inventor	Emil Martin
				Group Art Unit	1651
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	2105-01001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2002/0155166	10-24-2002	Choi et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AB	Abrams, J., Beneficial actions of nitrates in cardiovascular disease. <i>Am J Cardiol</i> , 1996. 77(13): p. 31C-7C	
	AC	Deinum, G., et al., Binding of Nitric Oxide and Carbon Monoxide to Soluble Guanylate Cyclase as Observed with Resonance Raman Spectroscopy. (1996) <i>Biochemistry</i> 35 (5), 1540-7	
	AD	Do, Y.S., et al., In-Stent Restenosis Limitation With Stent-Based Controlled-Release Nitric Oxide: Initial Results in Rabbits. <i>Radiology</i> , 2004. 230(2): p. 377-82	
	AE	Evans, C.H., et al., Osteoarthritis gene therapy. <i>Gene Ther</i> , 2004. 11(4): p. 379-89	
	AF	Friebe, A., and Koesling, D., Mechanism of YC-1-Induced Activation of Soluble Guanylyl Cyclase. (1998) <i>Mol Pharmacol</i> 53 (1), 123-7	
	AG	Gallo, O., et al., Role of Nitric Oxide in Angiogenesis and Tumor Progression in Head and Neck Cancer. <i>J Nat'l Cancer Inst</i> , 1998. 90(8): p. 587-96	
	AH	Lee, Y. C., et al., Human Recombinant Soluble Guanylyl Cyclase: Expression, Purification, and Regulation. (2000) <i>Proc Nat'l Acad Sci USA</i> 97(20), 10763-8	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. Send To Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

Application Number	10/777,008
Filing Date	February 11, 2004
First Named Inventor	Emil Martin
Group Art Unit	1651
Examiner Name	
Attorney Docket Number	2105-01001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AI	Martin, E., et al., YC-1 Activation of Human Soluble Guanylyl Cyclase has Both Heme Dependent and Heme Independent Components. <i>PNAS. Proc Nat'l Acad Sci USA</i> (Nov. 6, 2001) 98 (23), 12938-42	
	AJ	Okawa, H., et al., Preischemic Infusion of Alpha-Human a Trial Natriuretic Peptide Elicits Myoprotective Effects Against Ischemia Reperfusion in Isolated Rat Hearts. <i>Mol Cell Biochem</i> , 2003. 248(1-2): p. 171-7	
	AK	Sinnaeve, P., et al., Overexpression of a Constitutively Active Protein Kinase G Mutant Reduces Neointima Formation and In-Stent Restenosis. <i>Circulation</i> , 2002. 105(24): p. 2911-6	
	AL	Stasch, J. P., et al., Pharmacological actions of a Novel NO-Independent Guanylyl Cyclase Stimulator, BAY 41-8543: <i>in vitro</i> Studies. (2002) <i>Br J Pharmacol</i> 135 (2), 333-43	
	AM	Stasch, J., et al., NO and Haem Independent Activation of Soluble Guanylyl Cyclase: Molecular Basis and Cardiovascular Implications of a New Pharmacological Principle. <i>British J of Pharmacology</i> (2002) Vol. 136, No. 5, pp. 773-783	
	AN	Stone, J. R., et al., Spectral and Ligand-Binding Properties of an Unusual Hemoprotein, the Ferric Form of Soluble Guanylate Cyclase. <i>Biochemistry</i> (1996), 35, 3258-62	
	AO	Sunahara, R. K., et al., Exchange of Substrate and Inhibitor Specificities between Adenylyl and Guanylyl Cyclases. (1998) <i>J Biol Chem</i> . 273 (26), 16332-8	
	AP	Takahashi, M., et al., Cyclic GMP Production by ANP, BNP, and NO During Worsening and Improvement of Chronic Heart Failure. <i>Jpn Heart J</i> , 2003. 44(5): p. 713-24	
	AQ	Tomita, T., et al., Effects of GTP on Bound Nitric Oxide of Soluble Guanylate Cyclase Probed by Resonance Raman Spectroscopy. (1997) <i>Biochemistry</i> 36 (33), 10155-60	
	AR	Wedel, B., et al., Functional Domains of Soluble Guanylyl Cyclase. (1995) <i>J Biol Chem</i> 270 (42), 24871-5	
	AS	Zhao, Y., and Marietta, M. A., Localization of the Heme Binding Region in Soluble Guanylate Cyclase. (1997) <i>Biochemistry</i> 36 (50), 15959-64	
	AT	Zhao, Y., et al., Identification of Histidine 105 is the β 1 Subunit of Soluble Guanylate Cyclase as the Heme Proximal Ligand. (1998) <i>Biochemistry</i> 37 (13), 4502-9	
	AU	Zhao, Y., et al., A Molecular Basis for Nitric Oxide Sensing by Soluble Guanylate Cyclase. (1999) <i>Proc Nat'l Acad Sci USA</i> 96 (26), 14753-8	
	AV	PCT/US04/03853, PCT International Search Report dated October 28, 2004	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. Send To Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/777,008
		Filing Date	February 11, 2004
		First Named Inventor	Emil Martin
		Art Unit	1651
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	2105-01001

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none">Form PTO-1449 (w/copies of cited art)Acknowledgement Postcard		
<table border="1"><tr><td>Remarks</td><td></td></tr></table>			Remarks	
Remarks				

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	CONLEY ROSE, P. C.	
Signature		
Printed name	Carol G. Mintz	
Date	May 2, 2005	Reg. No. 38,561

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or Printed Name	Janna M. Melasecca		
Signature		Date	May 2, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and selection option 2